Literature DB >> 25552484

Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.

Raphaël Maréchal1, Jean-Baptiste Bachet2, Annabelle Calomme3, Pieter Demetter4, Jean Robert Delpero5, Magali Svrcek6, Jérôme Cros7, Armelle Bardier-Dupas8, Francesco Puleo3, Geneviève Monges9, Pascal Hammel10, Christophe Louvet11, François Paye12, Philippe Bachelier13, Yves Patrice Le Treut14, Jean-Christophe Vaillant15, Alain Sauvanet16, Thierry André17, Isabelle Salmon18, Jacques Devière3, Jean-François Emile19, Jean-Luc Van Laethem20.   

Abstract

PURPOSE: Aberrant activation of the hedgehog (Hh) pathway is implicated in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis. We investigated the prognostic and predictive value of four Hh signaling proteins and of the tumor stromal density. EXPERIMENTAL
DESIGN: Using tissue microarray and immunohistochemistry, the expression of Shh, Gli1, SMO, and PTCH1 was assessed in 567 patients from three independent cohorts who underwent surgical resection for PDAC. In 82 patients, the tumor stromal index (SI) was calculated, and its association with overall survival (OS) and disease-free survival (DFS) was investigated.
RESULTS: Shh and Gli1 protein abundance were independent prognostic factors in resected PDACs; low expressors for those proteins experiencing a better OS and DFS. The combination of Shh and Gli1 levels was the most significant predictor for OS and defined 3 clinically relevant subgroups of patients with different prognosis (Gli1 and Shh low; HR set at 1 vs. 3.08 for Shh or Gli1 high vs. 5.69 for Shh and Gli1 high; P < 0.001). The two validating cohorts recapitulated the findings of the training cohort. After further stratification by lymph node status, the prognostic significance of combined Shh and Gli1 was maintained. The tumor SI was correlated with Shh levels and was significantly associated with OS (P = 0.023).
CONCLUSIONS: Shh and Gli1 are prognostic biomarkers for patients with resected PDAC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25552484     DOI: 10.1158/1078-0432.CCR-14-0667

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  Biomarkers in pancreatic ductal adenocarcinoma.

Authors:  J Gallego; C López; R Pazo-Cid; F López-Ríos; A Carrato
Journal:  Clin Transl Oncol       Date:  2017-06-14       Impact factor: 3.405

2.  Sonic Hedgehog Protein is Frequently Up-Regulated in Pancreatic Cancer Compared to Colorectal Cancer.

Authors:  Madiha Niyaz; Mosin S Khan; Rauf A Wani; Omar J Shah; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2018-12-11       Impact factor: 3.201

3.  GSH2 promoter methylation in pancreatic cancer analyzed by quantitative methylation-specific polymerase chain reaction.

Authors:  Fei Gao; Hao-Jie Huang; Jun Gao; Zhao-Shen Li; Shu-Ren Ma
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

4.  Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer.

Authors:  Ying-Fang Wang; Hong-Yun Yang; Xiao-Qin Shi; Yue Wang
Journal:  Cancer Biol Ther       Date:  2018-09-27       Impact factor: 4.742

5.  Nicotine induces self-renewal of pancreatic cancer stem cells via neurotransmitter-driven activation of sonic hedgehog signalling.

Authors:  Mohammed H Al-Wadei; Jheelam Banerjee; Hussein A N Al-Wadei; Hildegard M Schuller
Journal:  Eur J Cancer       Date:  2015-12-12       Impact factor: 9.162

Review 6.  How does the tumor microenvironment play a role in hepatobiliary tumors?

Authors:  Fathima Kamil; Julie H Rowe
Journal:  J Gastrointest Oncol       Date:  2018-02

7.  Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.

Authors:  Yan Wang; Jung-Mao Hsu; Ya'an Kang; Yongkun Wei; Pei-Chih Lee; Shing-Jyh Chang; Yi-Hsin Hsu; Jennifer L Hsu; Hung-Ling Wang; Wei-Chao Chang; Chia-Wei Li; Hsin-Wei Liao; Shih-Shin Chang; Weiya Xia; How-Wen Ko; Chao-Kai Chou; Jason B Fleming; Huamin Wang; Rosa F Hwang; Yue Chen; Jun Qin; Mien-Chie Hung
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

8.  Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216.

Authors:  B Mohelnikova-Duchonova; M Kocik; B Duchonova; V Brynychova; M Oliverius; J Hlavsa; E Honsova; J Mazanec; Z Kala; I Ojima; D J Hughes; J E Doherty; H A Murray; M A Crockard; R Lemstrova; P Soucek
Journal:  Pharmacogenomics J       Date:  2016-08-30       Impact factor: 3.550

9.  TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.

Authors:  A K Thakur; J Nigri; S Lac; J Leca; C Bressy; P Berthezene; L Bartholin; P Chan; E Calvo; J L Iovanna; S Vasseur; F Guillaumond; R Tomasini
Journal:  Cell Death Differ       Date:  2016-03-04       Impact factor: 15.828

10.  Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

Authors:  Angela L McCleary-Wheeler; Ryan M Carr; Shanique R Palmer; Thomas C Smyrk; Jacob B Allred; Luciana L Almada; Ezequiel J Tolosa; Maria J Lamberti; David L Marks; Mitesh J Borad; Julian R Molina; Yingwei Qi; Wilma L Lingle; Axel Grothey; Henry C Pitot; Aminah Jatoi; Donald W Northfelt; Alan H Bryce; Robert R McWilliams; Scott H Okuno; Paul Haluska; George P Kim; Gerardo Colon-Otero; Val J Lowe; Matthew R Callstrom; Wen We Ma; Tanios Bekaii-Saab; Mien-Chie Hung; Charles Erlichman; Martin E Fernandez-Zapico
Journal:  Pancreatology       Date:  2019-11-21       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.